“This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor for distinct characteristics in this population. These insights may also prompt a reassessment of our management strategies and suggest a shift in our approach to intensified follow-up for both moderate
egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to
Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking. egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.
Led by Rahul Sharma MBBS, FRACP, and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients with Moderate-to-Severe Mitral Regurgitation are 3 Times Less Likely to be Treated Than Patients with Severe Mitral Regurgitation Despite Similar Untreated Mortality…
“These findings underscore the urgency of early intervention for patients with MR. The implications of delayed treatment, particularly in moderate-to-severe MR, cannot be overstated, as it may lead to poor patient outcomes.” Rahul Sharma, MBBS, FRACPDirector of Structural Interventions, Stanford Healthcare, Associate Director of the Cardiac Catheterization Laboratory and Clinical